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Astrocytes are a predominant glial cell type in the nervous systems, and are becoming
recognized as importantmediators of normal brain function aswell as neurodevelopmental,
neurological, and neurodegenerative brain diseases. Although numerous potential mecha-
nismshave been proposed to explain the role of astrocytes in the normal and diseased brain,
research into the physiological relevance of these mechanisms in vivo is just beginning. In
this review, we will summarize recent developments in innovative and powerful molecular
approaches, including knockout mouse models, transgenic mouse models, and astrocyte-
targeted gene transfer/expression, which have led to advances in understanding astrocyte
biology in vivo that were heretofore inaccessible to experimentation.We will examine the
recently improved understanding of the roles of astrocytes –with an emphasis on astrocyte
signaling – in the context of both the healthy and diseased brain, discuss areas where the
role of astrocytes remains debated, and suggest new research directions.
Keywords: astrocytes, knockout mice, transgenic mice, chemogenetics, viral gene transduction, glial cell
progenitors, GPCR, neuron–glia interactions
INTRODUCTION
Although astrocytes are the most abundant glial cell type in the
mammalian nervous system and have emerged as crucial regula-
tors of nervous system development, function, and health, our
understanding of the physiology of astrocytes remains limited.
Howdo astrocytes interact with neurons and other cell types of the
nervous system? What are the primary functions of astrocytes in
brain development, health, and disease? One challenge to address
these questions is identifying the function of individual astro-
cytic molecules that regulate brain function. A unique approach
to investigate the molecular basis of astrocyte activity consists of
manipulating the genome of higher organisms. The mouse rep-
resents a great animal model that has been used extensively for
genetic manipulation in neuroscience, leading to understanding
of neuronal functions in unprecedented detail. A concerted effort
in recent years to develop genetic approaches to study astrocytes
is guiding the ﬁeld into new territory and improving our under-
standing of interactions between neurons and astrocytes. Here
we will review techniques for genetic manipulation of astrocytes
and highlight the most recent innovative and elegant approaches
that are providing insight into fundamental roles of astrocytes in
pathophysiology in vivo. In particular, we will describe the main
molecular approaches used in this ﬁeld, including knockout (KO)
mouse models, transgenic mouse models, and astrocyte-targeted
gene transfer and expression using adeno-associated viral (AAV)
or in utero electroporation (IUE) approaches. We will also touch
on a remarkable recent study involving engraftment of genetically
modiﬁed human glial progenitors into the mouse brain, providing
insight into the role of human astrocytes in the unique cognitive
abilities of the human brain. The present review does not attempt
to be comprehensive; rather it highlights certain major themes and
areas of recent progress on the roles of astrocytes in brain func-
tion, with an emphasis on astrocyte signaling and in vivo studies.
For complementary reviews on astrocyte function in health and
disease with an emphasis on molecular approaches, readers are
directed to (Fiacco et al., 2009b; Figueiredo et al., 2011; Agulhon
et al., 2012; Nedergaard and Verkhratsky, 2012; Clarke and Barres,
2013; Freeman and Rowitch, 2013; Tong et al., 2013), as well as the
other contributions to this special topic.
STUDYING ASTROCYTE FUNCTION THROUGH GENE
DISRUPTION
The elimination of one or more speciﬁc genes in an animal model
is a reliable and widespread approach to discovering the func-
tion of speciﬁc proteins and the cell types expressing them. Many
genes have been identiﬁed, isolated, and subsequently manipu-
lated to fully or conditionally suppress their expression (Sikorski
and Peters, 1997; Grimm, 2006; Vogel, 2007). These molecular
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developments represent powerful tools that can be used in vivo to
aid in discovering the role of astrocytes in the healthy and diseased
brain.
FULL (CONSTITUTIVE) KNOCKOUT MOUSE MODELS
As research into astroglia physiology in vivo is still a newly develop-
ing ﬁeld, much information can be gleaned from the elimination
of a gene or the deletion of a functional domain of a protein in
astrocytes to shed light on the function of both the targeted gene
and astrocytes in general. The process of generating a new line of
KO mice is laborious, but has been reﬁned to maximize efﬁciency
(reviewed inHall et al., 2009; Limaye et al., 2009). Once the desired
gene is identiﬁed, gene targeting can be used to generate a KO
mouse. A targeting vector containing a neomycin-resistant marker
is inserted into embryonic stem (ES) cells via electroporation and
is introduced into the DNA through homologous recombination,
allowing complete removal of one or more exons from the gene of
interest (Figure 1A). This results in the production of a mutated
or truncated protein or, more often, no protein at all. ES cells that
do not take up the foreign construct are killed through exposure
to neomycin, and those that have successfully replaced the gene or
the exons of this gene survive and are subsequently microinjected
into mouse blastocysts, which are then grown in surrogate mouse
uteri. Strategic mating of the chimeric mice will ultimately result
in a mouse with the gene globally eliminated (Capecchi, 1989; Hall
et al., 2009; Limaye et al., 2009; Figure 1A).
Role of GFAP in the healthy and diseased brain
One of the ﬁrst genes that was removed in astrocytes is the gene
encoding glial ﬁbrillary acidic protein (GFAP; Lewis et al., 1984;
Reeves et al., 1989; Masood et al., 1993; McCall et al., 1996; Eng
et al., 2000). GFAP is a member of the family of intermediate
ﬁlament structural proteins, which, in the mature nervous system,
is found predominantly in protoplasmic and specialized astrocytes
of the central nervous system (CNS) as well as in satellite cells,
non-myelinating Schwann cells, and enteric glia in the peripheral
nervous system (PNS; Jessen et al., 1984; Eng, 1985; Kato et al.,
1990). Outside the nervous system, GFAP has also been detected
in some rare non-glial cells of the salivary glands (Achstatter et al.,
1986; Gustafsson et al., 1989), ﬁbroblasts (Hainfellner et al., 2001),
myoepithelial cells (Viale et al., 1991), liver stellate cells (Gard et al.,
1985), and lymphocytes (Riol et al., 1997). This protein is one
of the key elements of the cytoskeleton that contributes to the
morphology andmotility of astrocyte processes (Fuchs andWeber,
1994; Pekny and Pekna, 2004; Gomi et al., 2010; Middeldorp and
Hol, 2011) and is upregulated in reactive astrocytes (astrogliosis)
in essentially any CNS pathology (Eng and Ghirnikar, 1994; Eng
et al., 2000; Pekny and Nilsson, 2005; Sofroniew, 2009; Sosunov
et al., 2013). During development, GFAP is expressed widely in a
number of progenitor cell types giving rise to both neurons and
glia. For example, GFAP-expressing radial glia in the ventricular
zone (VZ) give rise to mature astrocytes, oligodendrocytes and
neurons, aswell as guiding subsequentmigration of neurons (Gotz
et al., 2002; Malatesta et al., 2003; Anthony et al., 2004; Merkle
et al., 2004).
The seminal studies reporting the ﬁndings obtained with the
GFAP KO mouse models were made by targeted deletion of the
GFAP gene in ES cells (Pekny et al., 1995; Liedtke et al., 1996;
McCall et al., 1996) or by targeted disruption of the GFAP gene by
insertion of a LacZ cassette (Gomi et al., 1995). These GFAP KO
mouse lines havebeenused to investigatewhether changes in astro-
cyte processes and their morphological structure can inﬂuence
brain morphogenesis and function, the physiology of adjacent
synapses, and functional recovery after CNS insults. The over-
all appearance of the GFAP KO mice is indistinguishable from
wild-type mice; they develop normally and display no gross alter-
ations in behavior or CNS morphology. This observation suggests
at ﬁrst that GFAP is not essential for normal brain morphogen-
esis and function. However, closer analyses have indicated the
involvement of GFAP in a wide variety of processes. First, these
mice display enhancedhippocampal long-termpotentiation (LTP)
and deﬁcient cerebellar long-term depression (LTD) in acute brain
slices fromadultmice, suggesting thatGFAP intermediate ﬁlament
protein is important for astrocyte–neuronal interactions and that
astrocyte processes play a vital role in modulating synaptic efﬁcacy
in the CNS (McCall et al., 1996; Shibuki et al., 1996). In agreement
with the cerebellar ex vivo ﬁndings, a signiﬁcant impairment of
eye blink conditioning was found in the GFAP KO mice, suggest-
ing that GFAP is required for normal communication between
Bergmann glia (specialized astrocytes) and Purkinje cells during
induction and maintenance of cerebellar LTD in vivo (Shibuki
et al., 1996). Second, morphological and functional alterations in
the blood–brain barrier (BBB), disorganization of white matter
architecture and vascularization, as well as hydrocephalus were
reported in 18–24 month GFAP KO mice, suggesting an involve-
ment of GFAP in the long-term maintenance of normal BBB and
CNS myelination (Liedtke et al., 1996). Third, when challenged by
diverse brain injuries in vivo, theGFAPKOmiceweremore vulner-
able to: (i) CNS mechanical trauma (Nawashiro et al., 1998; Otani
et al., 2006), (ii) cerebral ischemia (Nawashiro et al., 2000; Tanaka
et al., 2002), (iii) kainic acid-induced neurotoxicity (Otani et al.,
2006), and (iv) autoimmune encephalomyelitis (Liedtke et al.,
1998). This was indicated by: (i) increased brain hemorrhage and
mortality of mice; (ii) larger cortical infarct volume and profound
decrease in cerebral blood ﬂow; (iii) neurodegeneration; and (iv)
enhanced clinical course of autoimmune encephalomyelitis and
lesions, respectively. Conversely, other investigators have found
that suppressing astrocytic GFAP expression in reactive astrocytes
increases their basal levels of glial cell derived neurotrophic fac-
tor (GDNF), leading to improvement in neuronal survival from
metabolic and excitotoxic insults (Hanbury et al., 2003). Beneﬁcial
neuroprotective and regenerative effects have also been reported
after hippocampal and spinal cord injuries in mice lacking both
GFAP and vimentin, another astrocyte intermediate ﬁlament pro-
tein (Kinouchi et al., 2003; Menet et al., 2003; Wilhelmsson et al.,
2004). Collectively, these ﬁndings suggest that the GFAP com-
ponent of the astrocyte cytoskeleton plays an important role in
the physiology and pathology of the nervous system. However,
because GFAP is expressed in progenitor cells during develop-
ment giving rise to neurons, oligodendrocytes and astrocytes,
these ﬁndings have to be viewed carefully. Inducible GFAP KO
strategies can be used to circumvent this problem by removing
GFAP only from astrocytes after this developmental window has
closed (see below).
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FIGURE 1 | Schematic representation of the main genetic manipulations
to make knockout (KO) mice. (A) Conventional strategy for full (constitutive)
gene knockout. The targeted gene is inactivated following insertion of an
antibiotic (neomycin or neo) resistance gene within, or in place, of one of
several essential exons(s) through electroporation of a targeting vector in
murine embryonic stem (ES) cells and subsequent homologous
recombination. Totipotent embryonic ES cells with successful recombination
will survive neomycin treatment to be selectively chosen and injected in
mouse blastocysts. Blastocytes are then transferred to the uterus of
pseudopregnant females where they can differentiate into all cell types of a
chimeric mouse (red circles). After breeding the chimeric mice, the resulting
offspring will derive from the ES cells – as seen with the transmission of coat
color (red) – if the introduced ES cells become established into the germline
of the chimeric mouse. In the full KO, the gene of interest is knocked out in all
cell types (not only astrocytes) of the offspring. (B) Classical Cre-LoxP
strategy for conditional gene knockout. The creation of two mouse lines is
necessary. First, a ﬂoxed mouse line (green) is obtained by homologous
(Continued)
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FIGURE 1 | Continued
recombination in ES cells. Two LoxP sites are positioned in intronic regions
that ﬂank one or several essential exons of the targeted gene. In this mouse
line the targeted gene is normally expressed. Second, a Cre mouse line
(orange) created by classical transgenesis, following pronuclear injection of
the cDNA encoding the Cre-recombinase under the control of an
astrocyte-speciﬁc promoter. This line gives astrocyte selectivity to the
system. Breeding of the ﬂoxed mouse with the Cre mouse leads to the
generation of a new mouse line (green/orange-striped) in which the ﬂoxed
exon(s) are excised only in astrocyte-expressing Cre, while the targeted
gene remains functional in other cell types. In this case the
Cre-recombinase (orange squares) is constitutively expressed, i.e.,
inactivation of the targeted gene occurs as soon as the astrocyte-speciﬁc
promoter driving Cre-recombinase is active. (C) Inducible CreERT2-LoxP
strategy for temporal control of gene knockout. As in (B), a ﬂoxed mouse
line (green) and a CreERT2 mouse line (yellow) are necessary to obtain a
third mouse line (green/yellow-striped) in which the ﬂoxed exon(s) are
excised only in astrocyte-expressing CreERT2. In this mouse line, the
CreERT2-recombinase (yellow squares) is expressed in astrocytes but is
kept in the cytoplasmic compartment and is inactive. To achieve temporal
control of the gene knockout, CreERT2 activity (red/yellow squares) is
induced by synthetic steroid ligand (tamoxifen or 4-hydroxy-tamoxifen
capable of crossing the blood brain barrier) administrated systemically at any
chosen time. Binding of steroid to CreERT2 allows translocation of CreERT2
to the nucleus where recombination of ﬂoxed genes can occur selectively in
astrocytes while the targeted gene remains functional in other cell types.
In light of more recent evidence suggesting that astroglio-
sis is not a uniform process but rather a multifaceted response
with context-dependent reactions (reviewed in Sofroniew, 2009;
Sofroniew and Vinters, 2010), the GFAP KO mouse models will
continue to be valuable tools in future studies seeking to further
unravel the function of GFAP and astrocytes in the variety of
human brain challenges or diseases in vivo. These mouse models
will assist in understanding the stages when astrocytes are engaged
in beneﬁcial or detrimental functions. Furthermore, a number of
considerations can be taken into account which may lead to both a
re-evaluation of earlier ﬁndings using thesemice aswell as open up
new research directions. These include the following: (i) the het-
erogeneity of astrocyte morphology and physiology (Aley et al.,
2006; Emsley and Macklis, 2006; Lee et al., 2006; Matyash and Ket-
tenmann, 2010; Zhang and Barres, 2010; Oberheim et al., 2012;
Freeman and Rowitch, 2013; Schreiner et al., 2013); (ii) the vari-
ability of GFAP expression levels among this heterogeneous cell
population (Bernal and Peterson, 2011; Daniel-Christoph et al.,
2013); (iii) the ﬂuctuation of GFAP expression during circadian
light–dark cycles, hormonal cycles, developmental, or pathological
stages (Hajos, 2008); (iv) the existence of about eight alternatively
spliced GFAP isoforms that may execute distinct functions in spe-
ciﬁc subsets of astrocytes (Middeldorp and Hol, 2011); and (v) the
post-translational modiﬁcation of these different isoforms such
as phosphorylation and glycosylation that may inﬂuence GFAP
assembly into intermediate ﬁlaments (Middeldorp andHol, 2011).
Suitable GFAP isoform-speciﬁc KO models will be required in
future studies to address these issues. One way to investigate the
impact of alternative splicing of the GFAP gene in a mouse model
would be to selectively delete a single isoform. This can be accom-
plished by deleting a coding exon from the genome, introducing a
stop codon, inactivating the splice sites responsible for generating
a speciﬁc isoform, or overexpressing a dominant negative version
of a certain isoform (Moroy and Heyd, 2007). An alternative way
to investigate the impact of alternative GFAP splicing would be to
use antisense oligonucleotides to prevent the inclusion of a par-
ticular exon in the mature mRNA (Gebski et al., 2003; Dori et al.,
2005). Isoform-speciﬁc KO mouse models provide a compelling
approach to study how alternative splicing of the GFAP gene may
contribute to the regulation of pathophysiological CNS processes
in vivo.
Role of IP3R2 in normal synaptic transmission and plasticity
Another global KO of a gene in astrocytes is the gene encod-
ing the inositol-1,4,5-trisphosphate type 2 receptor (IP3R2). Two
constitutive IP3R2-deﬁcient mouse models have been obtained
through a variation of the gene targeting strategy. In one, the
targeting construct was generated by ﬂanking exon 3 of IP3R2
with two LoxP sites and ﬂanking the neo-cassette by FRT sites
(Li et al., 2005). In the other, exon 1 of the gene was fused with
a LacZ cassette (Futatsugi et al., 2005). Deletion of the IP3R2
subtype is a valuable tool in astrocyte research, as it is the only
functional IP3R subtype expressed by astrocytes and the main
mechanism by which astrocytes elevate intracellular Ca2+ lev-
els (Petravicz et al., 2008; Agulhon et al., 2010; Di Castro et al.,
2011; Takata et al., 2011). This mouse line has been critical to
address the concept of gliotransmission, which stipulates that
neuroactive molecules including neurotransmitters (called glio-
transmitters) are released from mature passive astrocytes in a
neuronally-induced and Ca2+-dependent manner downstream of
Gq protein-coupled receptors (Gq GPCRs) to quickly modulate
synaptic transmission and plasticity (illustrated and compre-
hensively discussed in Agulhon et al., 2008, 2012; Hamilton and
Attwell, 2010). Upon Gq GPCR activation, IP3 is produced
intracellularly, leading to astrocytic IP3R2 activation and Ca2+
release from the endoplasmic reticulum. Ex vivo and in vivo
studies demonstrate that Ca2+ transients in mature passive astro-
cytes are driven by metabotropic Gq GPCRs, which can be
activated by the spillover of neurotransmitters released from
presynaptic terminals (Porter and McCarthy, 1996; Wang et al.,
2006). Therefore, astrocytic Gq GPCRs are considered to be
the physiological link between neuronal activity and detectable
Ca2+ increases in mature astrocytes. However, it is important
to keep in mind that future studies using improved imag-
ing methods may reveal alternate sources of activity-driven
Ca2+ transients in astrocytes. For example, new membrane-
tethered genetically encoded Ca2+ indicators have allowed for
detection of previously unreported constitutive Ca2+ transients
(Shigetomi et al., 2013b; Tong et al., 2013).
The use of the IP3R2 KO mouse model was done to selec-
tively obliterate the endogenous Gq GPCR/IP3R2-mediated Ca2+
elevations. The initial studies using this mouse model reported
that removing astrocytic Gq GPCR/IP3R2-mediated Ca2+ ﬂuxes
did not affect basal and evoked excitatory synaptic transmission
(EPSCs), or short- and long-term plasticity (NMDA receptor-
dependent LTP) in the hippocampus ex vivo (Fiacco et al., 2007;
Petravicz et al., 2008; Agulhon et al., 2010). The implications
of these ﬁndings have already been well documented and dis-
cussed (Agulhon et al., 2008, 2010, 2012; Petravicz et al., 2008;
Fiacco et al., 2009a; Hamilton and Attwell, 2010; Kirchhoff, 2010;
Nedergaard and Verkhratsky, 2012). Recently, an ex vivo study
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replicated some of the above-described data by showing that hip-
pocampal NMDA receptor-mediated LTP is normal in IP3R2 KO
mice, supporting the initial ﬁndings that the IP3R2-mediated
internal Ca2+ store pathway is not involved in activity-evoked
gliotransmitter release at the hippocampal CA1–CA3 synapses
(Shigetomi et al., 2013b). Moreover, the authors of this study
discovered a novel mechanism based on transient receptor poten-
tial A1 (TRPA1)-mediated transmembrane Ca2+ ﬂuxes, through
which astrocytes can modulate LTP. They found that pharmaco-
logical blockade or genetic deletion of a recently described TRPA1
channel in astrocytes alters free basal Ca2+ levels, leading to a
decrease in Ca2+-dependent constitutive/homeostatic release of
D-serine, and thus LTP reduction – in support of a previous study
(Henneberger et al., 2010). Such Ca2+ rises are not the type of
neuronally-induced astrocyte Ca2+ elevations suggested to drive
fast release of gliotransmitters by mature astrocytes. Overall these
ﬁndings emphasize how different astrocyte Ca2+ sources (i.e.,
activity-evoked Gq GPCR/IP3R2-dependent Ca2+ elevations vs.
constitutive TRPA1-dependent basal Ca2+ dynamics) have dis-
tinct effects on LTP (Shigetomi et al., 2013b), and potentially
other physiological effects previously attributed to IP3R2-driven
astrocyte Ca2+ elevations.
Recent studies using IP3R2 KO mice in vivo reported that hip-
pocampal muscarinic or cortical NMDA receptor-mediated LTP is
diminished or abolished, suggesting a role for IP3R2-driven Ca2+
elevations in synaptic plasticity (Takata et al., 2011; Navarrete
et al., 2012). Two exciting new reports are providing a poten-
tial explanation for the differences observed between the early
and later studies using the IP3R2 KO. By using a broad range of
GqGPCR antagonists, Wang and coauthors excluded the occur-
rence of gliotransmission both ex vivo and in vivo (Wang et al.,
2012a,b), consistent with the prior ex vivo studies using the IP3R2
KO mice. Rather, they identiﬁed a mechanism by which astro-
cytic Gq GPCR/IP3R2-mediated Ca2+ elevations stimulate the
Na+, K+-ATPase, leading to a transient K+ uptake by astrocytes, a
decrease in the extracellular K+ concentration, and a subsequent
modulation of excitatory postsynaptic currents. This modulation
of synaptic transmission was not observed in the IP3R2 KO mice,
implying that astrocyte Gq GPCR/IP3R2/Ca2+-induced decrease
of extracellular K+ concentration endows astrocytes with a simple
and powerful mechanism for rapid modulation of neuronal activ-
ity (Wang et al., 2012a,b). Modulation of K+ uptake by astrocytic
Gq GPCRs was also observed ex vivo (Devaraju et al., 2013; Wang
et al., 2013). Rapid modiﬁcation of K+ uptake provides a mech-
anism which may be responsible for effects on neuronal activity
that hitherto have been ascribed to gliotransmission. Nevertheless,
synaptic properties are variable within the nervous system, and
astrocytes represent a genetically and functionally heterogeneous
group of cells (Zhang and Barres, 2010; Oberheim et al., 2012);
these cells are likely to exhibit different functions in different areas
of the CNS or even within the same area. Therefore, the differ-
ent effects of knocking out IP3R2 on neuronal activity support
the need to consider heterogeneity of astrocytes between differ-
ent brain regions when comparing data across studies. Further
investigation is necessary to determine the mechanisms involved
in activity-induced astrocytic Gq GPCR/IP3R2/Ca2+-mediated
modulation of neuronal excitability and LTP in vivo.
In our view, a fundamental and still open question remains
to be answered in order to address this issue thoroughly: do
neurons express IP3R2? If so, does this neuronal receptor
subtype play a role in speciﬁc types of synaptic transmission
and plasticity? Fully deleting IP3R2 abolishes spontaneous and
activity- or agonist-dependent Gq GPCR/IP3R2-mediated Ca2+
increases in astrocytes but leaves intact neuronal Ca2+ signaling
(Petravicz et al., 2008; Di Castro et al., 2011; Takata et al., 2011;
Chen et al., 2012; Navarrete et al., 2012; Wang et al., 2012a,b).
However, caution should be exercised in the interpretation of the
positive physiological data using this mouse model. Indeed, past
immunohistochemical studies aimed at identifying the expres-
sion of IP3R2 in neurons were inconclusive (Sharp et al., 1999;
Holtzclaw et al., 2002; Hertle and Yeckel, 2007), and most recent
antibodies against this IP3R subtype are of poor quality (Takata
et al., 2011; Chen et al., 2012). Additionally, functionally testing
whether neurons display IP3R2-mediated Ca2+ signaling would
require the use of double KOs for the two other IP3R subtypes
(IP3R1 and IP3R3), which is complicated because most of the
IP3R1-deﬁcient mice die in utero (Matsumoto et al., 1996). We
are then left with the possibility that some neurons, which also
have heterogeneous subtypes throughout the brain, may express
IP3R2 in addition to IP3R1 and/or IP3R3. Such a hypothesis, if
validated, could help address some of the discrepancies between
positive and negative ﬁndings using the IP3R2 KO mice. The
use of inducible conditional IP3R2 KO mice to selectively knock
out IP3R2 in neurons vs. astrocytes in adult mice appears to be
the next obvious step to help differentiate between neuronal vs.
astrocytic Gq GPCR effects on neuronal excitability and LTP in
vivo. Finally, the currently available and future inducible IP3R2
KO mouse models may help provide insight into brain pathol-
ogy; recent studies suggest that abnormal (increased) astrocytic
Ca2+ dynamics are linked to the symptoms of Alzheimer’s dis-
ease (Takano et al., 2007; Kuchibhotla et al., 2009; Grolla et al.,
2013), suggesting that controlling astrocytic Ca2+ homeosta-
sis might be a potential form of therapy for neurodegenerative
disease.
CONDITIONAL AND INDUCIBLE CONDITIONAL KNOCKOUT MOUSE
MODELS
The complete knock out of genes in mice has allowed researchers
to investigate the role of speciﬁc genes in vivo. When a gene is
selectively expressed in a speciﬁc cell type and/or tissue, a con-
stitutive KO is thus cell-speciﬁc and/or tissue-speciﬁc. However,
it is rare that genes are expressed by a single cell type. In such
instances, the phenotypes of KO mice can be very complex to
interpret and it is not uncommon for a KO mouse to display
embryonic lethality (Matsumoto et al., 1996), show no pheno-
type at all, or affect other gene products (Iacobas et al., 2004).
To overcome these obstacles, genes have been knocked out in a
cell-speciﬁc manner with the use of Cre recombinase/LoxP tech-
nology. Such gene KOs are referred to as conditional gene KOs
(cKO; Figure 1B). The site-speciﬁc recombination system of the
P1 bacteriophage using Cre and LoxP-ﬂanked genes is well doc-
umented (Sternberg and Hamilton, 1981), although it was only
much later that it was used in mouse lines to induce cell-speciﬁc
gene cKOs in non-nervous and/or nervous tissues (Gu et al., 1994;
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Morozov et al., 2003). In order to accomplish this, two mouse lines
are required: one that has been genetically engineered to express
the Cre site-speciﬁc DNA recombinase of bacteriophage P1 under
a cell-speciﬁc promoter (transgenic mice; Figure 2A), and a sec-
ond that has been made via homologous recombination in ES
cells expressing the 34-base-pair LoxP site (recognition site for Cre
recombinase) ﬂanking the gene of interest or one or more exons
of this gene. When these two mouse lines are crossed, the gene
or exons of interest are excised to obtain the desired cKO mouse
line (reviewed in Sauer, 1998; Figure 1B). While cKO mice are
very valuable tools, their use has been limited in the astrocyte ﬁeld
because thepromoters that are known tobe astrocyte speciﬁc in the
adult are also expressed in progenitor cells of the developing brain.
As a consequence, not only astrocytes, but also a large percentage
of neurons and oligodendrocytes, exhibit recombination when
using astrocyte-speciﬁc promoters to drive the expression of Cre
recombinase (Gotz et al., 2002; Malatesta et al., 2003; Anthony
et al., 2004; Merkle et al., 2004; Casper and McCarthy, 2006). This
limitation prompted investigators in the ﬁeld to develop trans-
genic mice that enable inducible cell-speciﬁc gene KOs in order
to recombine astrocytic genes postdevelopmentally (referred to
as inducible cKO mice; Figure 1C). To this end, mice have been
developedwhich express Cre recombinase fused to amutated form
of the human estrogen receptor (ERT2) that restricts the fusion
protein to the cytoplasm unless exposed to the estrogen analog
tamoxifen (or 4-hydroxy-tamoxifen; Feil et al., 1997). This form
of theCre recombinase, calledCreERT2, enters the nucleus to cause
cell-speciﬁc recombination only when tamoxifen is given to mice
FIGURE 2 | Schematic representation of the genetic modification
systems to make astrocyte-specific transgenic mice. (A) Conventional
strategy for conditional expression of a transgene selectively in astrocytes. A
transgene of interest is placed under the control of an astrocyte-speciﬁc
promoter; this cDNA construct is puriﬁed and microinjected into the male
pronucleus of fertilized murine eggs. Several copies of the DNA will be
randomly inserted in the mouse genome. Then, the eggs are transferred to
the oviduct of pseudopregnant females. The resulting offspring (green)
deriving from the eggs will display constitutive transgene expression
selectively in astrocytes as soon as the astrocyte-speciﬁc promoter is active,
while it will not be expressed in other cell types. (B)Tet-Off strategy for
inducible and temporal control of transgene expression selectively in
astrocytes. TheTeT-Off system has been used more frequently than the
Tet-On system, and is based on the tetracycline (tet) bacterial resistance gene
operon. The creation of two transgenic lines is required. The ﬁrst transgenic
line (orange) contains the tTA under the control of an astrocyte-speciﬁc
promoter: this line provides astrocyte selectivity to the system. The second
transgenic line (green) contains the transgene of interest under the control of
the tet operon (TetO) DNA-binding element fused to a minimal promoter from
cytomegalovirus. TheTetO promoter element can be activated upon binding
of the tetracycline transactivator (tTA) to drive ubiquitous expression.When a
tetracycline derivative, such as doxycycline, is given to the bigenic mice
(green/orange-striped – obtained from breeding the tTA line with theTetO
line) in the drinking water, doxycycline binds to tTA to prevent its interaction
with theTetO minimal promoter and thereby turn off transgene expression
selectively in astrocytes. Removing doxycycline from the drinking water of
the bigenic mice leads to binding of tTA to theTetO minimal promoter and
transcription of the transgene of interest within a week. This allows desired
temporal expression of the transgene selectively in astrocytes while it is not
expressed in other cell types. Additionally, this system allows testing whether
potential physiological or behavioral effects of the transgene are reversible by
putting the bigenic mice back on doxycycline.
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(Hayashi and McMahon, 2002). Thus, genetically engineered mice
expressing CreERT2 under the control of an astrocyte-speciﬁc pro-
moter (e.g.,GFAP,glutamate transporterGLAST,Aldh1l1orCx43)
allows study of the effect of gene deletion speciﬁcally in astrocytes
if tamoxifen is given to mice at later development stages (Eckardt
et al., 2004; Hirrlinger et al., 2006; Mori et al., 2006; Casper et al.,
2007; Figure 1C). One limitation of the CreERT2 inducible system
and inducible systems in general is that recombination efﬁciency
may be low and therefore the phenotypes generated may be more
subtle, as has been reported for Cx43 compared to ﬂoxed reporter
genes (Casper et al., 2007).
Role of CB1R in working memory
Multiple inducible cKO mice have been recently developed to
study astrocytic function in vivo. One example is a tamoxifen-
inducible cKO mouse speciﬁcally lacking cannabinoid type-1
receptor (CB1R) expression in astrocytes (Han et al., 2012). A
mouse line carrying a LoxP-ﬂanked CB1R (Marsicano et al., 2003)
was crossed with a line expressing CreERT2 under the control of
the human GFAP promoter (Hirrlinger et al., 2006). The resulting
new line of mice (GFAP-CB1R-KO)has beenused to investigate the
mechanisms underlying impairment of workingmemory,which is
one of the most important deleterious effects of marijuana intox-
ication in humans (Ranganathan and D’Souza, 2006) and animals
(Lichtman and Martin, 1996; Wise et al., 2009). Understanding
the side-effects associated with the use of marijuana has impor-
tant clinical implications because the derivatives of marijuana or
synthetic cannabinoids represent promising therapeuticmolecules
for several human conditions, including pain, nausea, seizures,
ischemia, cerebral trauma, and tumors (Lemberger, 1980; Carlini,
2004; Hall et al., 2005). The endocannabinoid system has recently
emerged as an important neuromodulatory system, and the CB1R
(GPCR predominantly coupling to Gi proteins) is highly abun-
dant in the CNS (Herkenham et al., 1990; Matsuda et al., 1990). In
particular, the CB1R is expressed in glutamatergic and GABAergic
neurons (Herkenham et al., 1990; Kawamura et al., 2006) as well as
in astrocytes (Navarrete and Araque, 2008; Han et al., 2012) of the
hippocampal CA1 area, an area that contributes to spatial work-
ing memory (SWM). Because past studies have established that
CB1Rs mediate retrograde inhibition of neurotransmitter release,
control neuronal excitability, and regulate short- and long-term
plasticity (Di Marzo et al., 1994; Kreitzer and Regehr, 2001; Alger,
2002; Wilson and Nicoll, 2002; Freund et al., 2003; Chevaleyre
et al., 2006; Maldonado et al., 2006; Heifets and Castillo, 2009;
Kano et al., 2009), research on the function of CB1R signaling in
pain (Kato et al., 2012), aversive memory (Marsicano et al., 2002),
epilepsy (Monory et al., 2006), food intake (Bellocchio et al., 2010),
analgesia (Zimmer et al., 1999), or development (Jin et al., 2004)
has focused mainly on neuronal CB1Rs using neuronal-speciﬁc
CB1R KO mouse models. However, Han et al. (2012) report an
unappreciated, yet major, role of astrocytic CB1Rs in SWM. Their
results show that acute cannabinoid exposure in vivo elicits a
previously unreported form of LTD at CA3–CA1 hippocampal
synapses, which is associated with an impairment of SWM; both
effects are abolished in tamoxifen-treated GFAP-CB1R-KO, but
conserved in mice lacking CB1R in glutamatergic or GABAergic
neurons (Han et al., 2012). These ﬁndings strongly suggest that
astrocytic CB1R is a primary mediator of cannabinoid-induced
LTD. Based on further in vivo pharmacological studies, the authors
speculated that their ﬁndings are consistent with the possibility
that acute exogenous cannabinoid exposure leads to glutamate
release from astrocytes, which in turn could activate extrasynap-
tic NR2B-containing NMDA receptors to trigger AMPA receptor
internalization at CA3–CA1 synapses. These events could eventu-
ally induce cannabinoid-mediated LTD at these synapses, altering
hippocampal SWM. However, several points should to be kept
in mind when considering this interpretation of the data, which
might imply a substantially more complex mechanism at the
CA1–CA3 synapses: (i) the apparent mechanistic discrepancy
between this in vivo cannabinoid-induced LTD and previous ex
vivo “gliotransmission” studies suggesting that astrocytic CB1R-
mediatedCa2+ increases trigger the release of glutamate to activate
pre-synaptic mGluRs that leads to glutamate presynaptic release
and subsequent potentiation of postsynaptic NMDA receptor-
mediated currents (Navarrete and Araque, 2008, 2010); (ii) the
current debate as to whether astrocytes actually release glutamate
in a GPCR/Ca2+-dependent manner in vivo (Wang et al., 2012a
compared to Navarrete et al., 2012); (iii) the emerging evidence
that astrocyte GPCR/Ca2+-dependent release of glutamate occurs
in the early steps of inﬂammatory processes rather than during
normal physiology (Agulhon et al., 2012; Pascual et al., 2012); (iv)
the recent ﬁndings suggesting that astrocytic GPCR/Ca2+ trig-
gers an increase of K+ uptake (Wang et al., 2012a,b; Devaraju
et al., 2013); and (v) a past study reporting that LTD is modulated
by astrocytic K+ uptake (Janigro et al., 1997). Further inves-
tigation should help determine whether cannabinoid-induced
LTD is due to an increase of extracellular glutamate, a decrease
of extracellular K+, a combination of both, or some other
mechanism.
Role of DRD2 in neuroinﬂammation
Astrocytes become reactive in nearly all brain pathologies, and
play important roles in neuroinﬂammation, a common fea-
ture of the aging brain and most neurological disorders and
neurodegenerative diseases (Sofroniew, 2009; Sofroniew and
Vinters, 2010). Changes in reactive astrocytes include upregula-
tion of GFAP expression (Pekny and Nilsson, 2005), secretion
of inﬂammatory mediators from astrocytes (Lucas et al., 2006;
Peng et al., 2006; Farina et al., 2007; Brambilla et al., 2009;
Steele and Robinson, 2012), and altered expression of astrocytic
GPCRs (Aronica et al., 2003; Hamby et al., 2012). One such
GPCR is the dopamine D2 receptor (DRD2) that couples to Gi
(Missale et al., 1998) and is expressed not only in neurons, but
also in astrocytes (Bal et al., 1994; Khan et al., 2001; Luo et al.,
2009). Downregulation of DRD2 expression has been reported
in the brain of the elderly (Kaasinen et al., 2000), suggesting
that astrocytic DRD2 signaling may be involved in neuroinﬂam-
mation that occurs in the CNS during aging and disease. A
recent study has investigated this question using both astrocyte-
speciﬁc cKO and tamoxifen-inducible cKO mouse models (Shao
et al., 2013). Several complementary methodological approaches
have been used, including immunohistochemistry, biochemistry,
and molecular biology to show that DRD2-deﬁcient astrocytes
show robust GFAP upregulation in the substantia nigra of aged
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mice. Moreover,DRD2-deﬁcient astrocytes were found to produce
more proinﬂammatory mediators than their wild-type counter-
parts, suggesting that astrocytic DRD2 is a key negative regulator
of neuroinﬂammation. To identify the downstream effectors of
DRD2 that might be involved in the regulation of inﬂamma-
tory mediator production, microarray analysis was carried out
and showed a pronounced decrease of the small heat-shock
protein αB-crystallin (CRYAB) in DRD2-deﬁcient astrocytes, a
protein known to display anti-inﬂammatory and neuroprotec-
tive activities (Ousman et al., 2007; Bhat and Steinman, 2009).
These ﬁndings suggest that activation of astrocytic DRD2 con-
trols CRYAB expression to suppress inﬂammatory responses in
astrocytes and thus contribute to the maintenance of the immune
state balance under normal conditions (Shao et al., 2013). The
implications of these ﬁndings are profound in age-related dis-
eases, where a decrease of DRD2 signaling in astrocytes may lead
to an abnormal increase of proinﬂammatory mediator release,
and underlie the progression of cognitive and motor function
impairments. Therefore, the astrocyte DRD2 signaling pathway
could be a potential target for therapy of several neurological,
neuroinﬂammatory, and neurodegenerative disorders, in which
production of inﬂammatory mediators is a common element
(Lucas et al., 2006).
It is interesting, however, to note that activation of another
Gi GPCR, called CXCR4 in cultured cortical astrocytes has pre-
viously been reported to increase release of the proinﬂammatory
cytokine tumor necrosis factor α (TNFα; Bezzi et al., 2001), and
not to negatively control the release of proinﬂammatorymolecules
as reported by Shao et al. (2013). Several obvious possibilities
may explain these differences: (i) astrocytic Gi signaling triggers
different cellular mechanisms depending on whether the stud-
ies are performed in vivo vs. ex vivo cultures; (ii) astrocytic Gi
signaling leads to distinct responses depending on the area of
the brain (e.g., substantia nigra vs. cortex); or (iii) astrocytic
Gi GPCRs are involved in different functions depending on the
developmental stage (mature vs. immature astrocytes). Addition-
ally, another possibility that has not been addressed thoroughly
in the ﬁeld when investigating the role of astrocyte signaling in
general is that different astrocytic Gi GPCRs may activate dis-
tinct signaling pathways even though they are known to couple
to Gi proteins. In other words, depending on the endogenous or
synthetic agonist used to active a speciﬁc Gi GPCR, this recep-
tor may show a different bias toward other G proteins over Gi
or different functional selectivity for β-arrestin recruitment over
Gi activation (Allen et al., 2011; Zidar, 2011; Audet et al., 2012;
Blattermann et al., 2012; Hiller et al., 2013). The depth of the
complexity of GPCR signaling is now becoming familiar terri-
tory to receptor biologists, yet the application of this knowledge
to the astrocyte ﬁeld remains extremely limited. Therefore, ﬁnd-
ings relative to astrocytic GPCR signaling (coupling to Gq, Gi,
or Gs proteins) in physiology and pathology likely reﬂect the
complex interactions of multiple signaling pathways and pro-
vides an explanation for seemingly contradictory observations.
Examples of this have already been observed relative to astrocyte
Ca2+ signaling which is traditionally ascribed to Gq GPCR sig-
naling pathways, yet astrocytic Gi-coupled GABAB and CB1Rs
also have been reported to evoke Ca2+ elevations in astrocytes
(Serrano et al., 2006; Navarrete and Araque, 2008). Future studies
using biased ligands in combination with astrocyte-speciﬁc cKOs
of speciﬁc G proteins or β-arrestins is one approach to elucidate
the role of astrocyte signaling molecules in brain function and
dysfunction.
STUDYING ASTROCYTE FUNCTION THROUGH GENE
EXPRESSION OR CELL-SPECIFIC RESCUE OF GLOBAL
GENE KNOCKOUT
As methods for generating full or inducible conditional gene
KO have been useful in deciphering some of the astrocyte gene
functions in vivo, constitutive, inducible, and/or reversible regu-
lation of gene expression represent other powerful approaches for
understanding astrocyte function. To this end, four molecular
approaches can be used: (i) expression of a genetically modi-
ﬁed gene (transgene); (ii) reversible regulation of an endogenous
gene; (iii) viral transduction of genes; or (iv) in utero gene
electroporation (IUE).
TRANSGENE EXPRESSION
Conventional (Figure 2A) and inducible (Figure 2B) transgenesis
allowing for astrocyte-speciﬁc expression of transgenes, consti-
tutively or at speciﬁc times, have been used in the ﬁeld. These
approaches employ a small transcriptional unit derived from
astrocyte-speciﬁc promoters. Of importance for the topic of
this review, mapping of the transcriptional regulatory elements
of the GFAP promoter has been critical to develop regulatory
units (promoters) of small size to direct transgene expression in
the majority of astrocytes in vivo without signiﬁcant expression
in other cell types in the brain (Masood et al., 1993; Brenner,
1994; Brenner et al., 1994). Other astrocyte-speciﬁc promoters
have also been used successfully to drive transgene expression
in astrocytes, such as Cx30, Cx43, S100b, Aldh1l1, or GLAST
promoters (reviewed in Pfrieger and Slezak, 2012). The DNA
construct containing a promoter fused to the transgene of inter-
est is microinjected into the male pronucleus of fertilized eggs
for random insertion in the mouse genome, followed by transfer
of the fertilized eggs to the oviduct of pseudopregnant recipient
females (Cho et al., 2009; Figure 2A). The resulting pups are iden-
tiﬁed as transgenic by polymerase chain reaction and checked for
astrocyte-speciﬁc transgene expression. This constitutive gain-of-
function approach however does not provide temporal control of
the transgene expression,which can be problematicwhen studying
the function of a transgene during developmental stages as men-
tioned above (Gotz et al., 2002; Malatesta et al., 2003; Anthony
et al., 2004; Merkle et al., 2004; Casper and McCarthy, 2006).
To overcome this limitation, inducible transgenic mouse mod-
els have been developed. The most commonly used method to
temporally control gene expression in mouse models is based on
the tet-operon/repressor and the estrogen (tetracycline) recep-
tor ligand-binding domain (Gossen and Bujard, 1992; Baron
and Bujard, 2000; Mansuy and Bujard, 2000; Saunders, 2011;
Figure 2B). This system is bi-transgenic, which means that it
involves the mating of two different transgenic mouse lines in
order to produce a new tetracycline-regulated transgenic mouse
line designed to activate the expression of a transgene in a spe-
ciﬁc cell type at a speciﬁc time point. The ﬁrst line contains an
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astrocyte-speciﬁc promoter driving the expression of the tetra-
cycline (tet) transactivator (tTA). The second line carries the
transgene of interest driven by the tet operon (TetO)DNA-binding
element fused to a minimal promoter from cytomegalovirus. In
this system, bigenic mice are maintained on tetracycline (doxycy-
cline) to block transgene expression.When doxycycline is removed
at a given time, tTA then binds to the TetO minimal pro-
moter leading to targeted expression of the transgene of interest
(Figure 2B).
Role of astrocytic Gq GPCR signaling in physiology and behavior
One important limitation in addressing the role of astrocytic
GPCR signaling in neurophysiology has been the inability to phar-
macologically activate astrocytic GPCRs in a cell type-speciﬁc
manner. Indeed, astrocytes in vivo express members of most of
the different families of GPCRs linked to the diverse array of
intracellular signaling cascades (Porter and McCarthy, 1997) that
are also known to be expressed by neurons. Therefore, the use
of pharmacological approaches consisting of agonist application
ex vivo or in vivo does not allow cell-speciﬁc GPCR activation.
Therefore, interpretation of the ﬁndings is made difﬁcult by direct
activation of neuronal (but also other cell type) receptors by the
applied agonist in addition to the intended astrocytic targets. As a
consequence, it has been difﬁcult to determine the effect of selec-
tively stimulating astrocytic Gq GPCR-mediated Ca2+ signaling
cascades on physiological processes such as synaptic transmission
and plasticity. This complication has led investigators to consider
previous reports of gliotransmission with caution.
Thus, advances in this ﬁeld depend upon the development
of novel tools to better address the physiological relevance of
astrocytic Gq GPCR Ca2+ signaling. In order to overcome some
of the limitations associated with traditional pharmacological
approaches, two novel transgenic mouse models were developed
(Fiacco et al., 2007; Agulhon et al., 2013). In the ﬁrst model, a
novel Gq GPCR is expressed selectively in astrocytes that is not
expressed by other cell types in the brain, is not activated by
endogenous ligands released in brain, and whose ligand, the
peptide FMRF, does not activate endogenous brain Gq GPCRs
(Fiacco et al., 2007). The novel receptor, the so-called Mas-related
gene A1 (MrgA1), is a member of a family of GPCRs normally
expressed in speciﬁc subsets of nociceptive sensory neurons in
the spinal cord (Dong et al., 2001), but is not found in the
brain. The MrgA1 receptor is targeted to astrocytes using the
inducible Tet-Off system (Figure 2B). In one transgenic mouse
line the green ﬂuorescent protein (GFP)-tagged MrgA1 recep-
tor is transcribed from the TetO promoter. When crossed with
a second transgenic line in which tTA is targeted to astrocytes
using the human GFAP promoter, a bigenic line (referred to
as the MrgA1 mice) is obtained, in which MgrA1-GFP is selec-
tively expressed in the vast majority of astrocytes in the absence
of doxycycline (Fiacco et al., 2007). Several studies using this
novel transgenic MrgA1 mouse model have shown that increasing
astrocytic MrgA1-mediated Ca2+ ﬂuxes does not lead to glio-
transmission ex vivo and in vivo, suggesting that astrocytes do not
release gliotransmitters in a Gq GPCR/Ca2+-dependent manner
(Fiacco et al., 2007; Agulhon et al., 2010; Wang et al., 2012a,b).
Rather, it has been reported that astrocytic MrgA1R-mediated
Ca2+ elevations potentiate astrocyte glutamate and K+ uptake
(Wang et al., 2012a,b, 2013; Devaraju et al., 2013), suggesting that
the mechanisms by which agonist-induced astrocyte Gq GPCR
activation modulates neuronal activity may be different than pre-
viously thought, in agreement with previous and most recent
ﬁndings (Fiacco et al., 2007; Agulhon et al., 2010; Wang et al.,
2013). It is important to bear inmind that agonist-evoked stimula-
tion of Gq GPCRs, including MrgA1Rs, generates Ca2+ elevations
that may not recapitulate some endogenous Ca2+ elevations in
astrocytes which often remain conﬁned to ﬁne processes. One
strategy in future studies could be to employ a caged version of
FMRF to locally stimulate astrocyte Ca2+ elevations by activa-
tion of a Gq signaling pathway, which may more closely resemble
the subset of microdomain astrocytic Ca2+ elevations which have
been observed in astrocytes in vivo.
More recently, another transgenic mouse line has been devel-
oped in order to facilitate investigation of the role of astrocytic Gq
GPCR signaling in vivo (Agulhon et al., 2013). One of the limi-
tations of the MrgA1 mice is that the MrgA1 FMRF ligand does
not cross the BBB, making in vivo studies more invasive as surg-
eries would be required in order to infuse FMRF into the brain of
freely moving mice. Additionally, endogenous MrgA1 is expressed
in sensory nerve terminals, preventing the use of MrgA1 mice
to study spinal cord astrocytes (as FMRF may diffuse and activate
endogenous MrgA1 in nociceptive sensory neurons). To overcome
some of these obstacles, a new GFAP-hM3Dq mouse line was cre-
ated (Agulhon et al., 2013). The innovation of this mouse line
is based on the use of a novel genetically engineered Gq GPCR
(called hM3Dq) that does not respond to endogenous ligands,
but instead responds to an inert synthetic ligand (clozapine-N-
oxide, CNO) that crosses the BBB and activates signaling cascades
in a similar fashion as endogenous Gq GPCRs (Armbruster et al.,
2007). Such new chemogenetic technology (called designer recep-
tors exclusively activated by a designer drug, or DREADD) has
recently led to several important discoveries in neuronal function
(e.g., Alexander et al., 2009; Ferguson et al., 2011; Atasoy et al.,
2012; Garner et al., 2012), and is now being applied to astro-
cytes for the ﬁrst time (Agulhon et al., 2013). This mouse line
was made through conventional transgenesis using a construct
containing the human GFAP promoter driving the expression
of hM3Dq (Figure 2A). Inducible and reversible expression of
the transgene is not a constraint when using the DREADD tech-
nology, as hM3Dq can be activated postdevelopmentally through
intraperitoneal CNO injection. Immunohistochemical screening
in adult mice indicates that expression of hM3Dq is restricted
to astrocytes within the CNS, and in non-myelinating Schwann
cells of sympathetic, sensory, and sciatic nerves, as well as satel-
lite cells in sympathethic, parasympathetic, and sensory ganglia
within the PNS. Such expression is expected for a GFAP-driven
transgene and allows CNO-induced global stimulation in GFAP+
glial cells within the CNS and PNS. This provides a power-
ful approach, as it can reveal most of the physiological and
behavioral phenotypes mediated by GFAP+ glial cell Gq GPCR
signaling. Acute CNO intraperitoneal injections of GFAP-hM3Dq
mice resulted in previously unreported and long-lasting (minutes
to hours) modulation of autonomic nervous system (ANS) func-
tion, including increased heart rate, blood pressure, and saliva
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formation, as well as decreased body temperature. Furthermore,
changes in activity-related behavior and motor coordination
were observed in CNO-treated GFAP-hM3Dq mice. To address
whether ANS and activity-related effects were due to Ca2+ or
other signaling pathways downstream of Gq GPCR activation,
the GFAP-hM3Dq mice were crossed with IP3R2 KO mice in
order to generate GFAP-hM3Dq mice in which IP3R2-dependent
Ca2+ increases were abolished. Interestingly, CNO-treated GFAP-
hM3Dq/IP3R2-deﬁcient mice exhibited similar autonomic and
motor modulation as CNO-treated GFAP-hM3Dq mice. These
ﬁndings suggest that CNO-induced phenotypes are not dependent
on IP3R2-dependent Ca2+ increases. Thus, other (non-Ca2+) sig-
naling molecules activated by Gq GPCRs in GFAP+ glial cells
may be important contributors to the functional effects of CNO.
Collectively, these ﬁndings open new avenues into investiga-
tion of GFAP+ glial cell (astrocyte, non-myelinating Schwann
cell, satellite cell) function in animal physiology. Further stud-
ies employing local CNO infusion into speciﬁc regions of the CNS
or PNS, and speciﬁc blockers of Gq GPCR signaling molecules
(e.g., protein kinase C or βγ-dependent activation of signaling
cascades), will help dissect out the areas of the nervous sys-
tem and the signaling pathways that are responsible for each
of the CNO-induced phenotypes. Viral transduction of hM3Dq
in wild-type mice is also a potential strategy to help deter-
mine what areas of the CNS vs. PNS are involved in the effects
observed in CNO-treated GFAP-hM3Dq mice. Finally, when
speciﬁc markers of different subpopulations of CNS astrocytes
become available, it will be possible to use new promoters to create
transgenic mice expressing hM3Dq in distinct subsets of astro-
cytes. This will allow determination of whether a speciﬁc subset
of astrocytes is responsible for all of the phenotypes observed in
CNO-treated GFAP-hM3Dq mice, or whether different subsets of
astrocytes are responsible for distinct phenotypes. Clearly, there
is much to be learned with regard to the role of astrocytes, and
more generally of GFAP+ glial cells, in complex physiology and
behavior. Collectively, the ﬁndings of this study point to astro-
cytes as potential therapeutic targets for some ANS or motor
dysfunctions.
CELL-SPECIFIC RESCUE OF A GENE KNOCKOUT
Another powerful molecular approach is to constitutively knock
out a particular gene product and then rescue it in a speciﬁc cell
population. This provides information on the contribution of a
speciﬁc cell type to the phenotype produced by the full KO of
the protein. This technique employs a LoxP-ﬂanked selectable
neo marker and transcriptional/translational stop cassette (called
neostop) located in the endogenous gene of interest to generate
a null mutant that can be activated by Cre-mediated recombi-
nation. This construct is placed into a targeting vector, which
is inserted into ES cells and introduced into the mouse genome
through homologous recombination (Müller, 1999; Figure 1A) to
eventually generate a mouse line in which expression of the tar-
geted endogenous gene is suppressed. When this Cre responding
mouse line is crossed with a transgenic line expressing Cre recom-
binase under a cell type-speciﬁc promoter, recombination of LoxP
sites excises the neostop cassette, thus re-activating expression of
the endogenous gene conditionally (Figure 1B) and with temporal
control in a speciﬁc cell population (Figure 1C). This approach is
powerful in the sense that it enables study of important questions
regarding the phenotype reversibility of certain diseases involv-
ing the loss of a single gene function, and thus has the potential
to open doors for future therapeutic approaches (Dragatsis and
Zeitlin, 2001). By providing gain- and loss-of-function informa-
tion, this approach has led to recent important steps forward in
the understanding of the role of astrocytes in autism spectrum
disorders.
ROLE OF ASTROCYTE MeCP2 IN RETT’S SYNDROME
Rett’s syndrome (RTT) is an X-chromosome-linked autism spec-
trum disorder caused by the loss of function of the epigenetic
factor methyl-CpG-binding protein 2 (MeCP2; Amir et al., 1999;
Chahrour and Zoghbi, 2007). MeCP2 aberrations result in a
constellation of neuropsychiatric, neuroanatomical, and neuro-
physiological abnormalities as well as autonomic dysfunctions,
such as respiratory abnormalities. Delayed neuronal maturation
and synaptogenesis, sparse and short dendritic spines (Fukuda
et al., 2005), impaired synaptic transmission and plasticity (Dani
et al., 2005; Asaka et al., 2006; Moretti et al., 2006), and altered
number of glutamatergic synapses and expression of excitatory
glutamate transporter VGLUT1 (Chao et al., 2007) were detected
in global MeCP2 KO mouse lines (also called RTT mouse mod-
els). Although no unifying principle on MeCP2 function has yet
emerged, it has been reported that MeCP2 acts as a transcrip-
tional repressor, activator or RNA-binding protein (Nan et al.,
1998; Colantuoni et al., 2001; Chahrour et al., 2008). Most studies
have been directed toward understanding the in vivo mecha-
nisms of neuronal MeCP2 (Akbarian et al., 2001) using different
neuronal-speciﬁc cKO mouse models, which led to the thought
that the primary cause of RTT is cell autonomous, i.e., result-
ing from a lack of functional MeCP2 in neurons (Chen et al.,
2001; Guy et al., 2001; Luikenhuis et al., 2004). However, more
recent studies have shown that MeCP2 is also expressed in all
glial cell types, including astrocytes, oligodendrocyte progenitor
cells, oligodendrocytes, and microglia (Ballas et al., 2009; Derecki
et al., 2012). In particular, in vitro studies have shown that astro-
cytic MeCP2 supports normal neuronal morphology, indicating a
non-cell autonomous inﬂuence of MeCP2 on neuronal function
(Ballas et al., 2009; Maezawa et al., 2009). Global re-expression
of the MeCP2 gene postnatally in full MeCP2 KO mice demon-
strated disease reversibility in this RTT mouse model, suggesting
that the neurological defects in MeCP2 disorders are not per-
manent (Guy et al., 2007). Based on these studies, Lioy et al.
(2011) asked whether astrocytic MeCP2 may also have a role
in rescuing RTT neuropathological symptoms in vivo in order
to determine the contribution of astrocytes to the symptoms of
RTT. They used a genetically engineered mouse line in which the
endogenous MeCP2 gene is globally silenced by insertion of a
LoxP-ﬂanked stop cassette, but can be conditionally activated by
stop cassette deletion via Cre-mediated excision (MeCP2lox−Stop
mice; Guy et al., 2007). When these MeCP2lox−Stop mice were
crossed with mice expressing CreERT2 under a human GFAP
promoter (hGFAP–CreERT2), (Hirrlinger et al., 2006), the result-
ing new mouse line (MeCP2lox−Stop::hGFAP–CreERT2) was thus
speciﬁcally designed for the investigation of astrocytic function
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in RTT (Lioy et al., 2011). The MeCP2lox−Stop::hGFAP–CreERT2
mice are globally deﬁcient in MeCP2 until injected with tamox-
ifen, which induces the excision of the Lox-stop cassette in the
endogenous MeCP2 gene, restoring the expression of MeCP2
in an astrocyte-speciﬁc manner. Strikingly, it was found that
re-expression of MeCP2 speciﬁcally in astrocytes signiﬁcantly
improved locomotion, anxiety levels, breathing patterns, and
average life span, indicating that astrocytes are involved in the
neuropathology of RTT and that restoring astrocyte MeCP2 can
ameliorate four consistent and robust RTT-like symptoms. Addi-
tionally, restoration of MeCP2 in astrocytes in the global KO mice
exerted a non-cell-autonomous positive effect on KO neurons in
vivo, restoring normal dendritic arborization and increasing lev-
els of VGLUT1. Altogether, these ﬁndings suggest that astrocytic
MeCP2 gene replacement is well-suited as a therapeutic strat-
egy. Therefore, these ﬁndings have major implications not only
for improving the understanding of astrocyte function in patho-
physiology but also have valuable clinical implications (Gadalla
et al., 2013; Garg et al., 2013). Deciphering the cellular (astro-
cyte vs. neuron) and molecular underpinnings of RTT is likely
to contribute to the understanding of the pathogenesis of a
broader class of autism spectrum disorders. Finally, the use of
conditional endogenous gene repair mutations has a clear appli-
cation for studying astrocytic contributions to other single gene
diseases.
VIRAL GENE TRANSDUCTION STRATEGIES
A new technique that is gaining momentum in the study of astro-
cyte function is viral-mediated delivery of transgenic constructs to
express or perturb a protein or molecule of interest. This strategy
offers an attractive alternative to generation of transgenic mouse
lines, which can be very time consuming and expensive due to
costs associated with maintenance of animal lines and genotyp-
ing.Viralmediated gene delivery is reviewed in detail in this special
issue (Merienne et al., 2013) and therefore this section will focus
mainly on a particular application of this approach for the study
of astrocyte Ca2+ activity.
Brieﬂy, in these experiments, a transgenic construct is inserted
into a recombinant AAV vector which is then injected into the
brain of wild-type mice. Approximately 2 weeks is sufﬁcient for
the viral vector to be incorporated into the host genome and for
high expression of the transgenic construct to occur (Ortinski
et al., 2010; Xie et al., 2010; Shigetomi et al., 2013a). Several AAV
serotypes have been generated that show tropism preferentially
for neurons or astrocytes or a combination of cells (Ortinski et al.,
2010). The AAV 2/5 pseudotype shows the strongest tropism for
astrocytes and therefore appears to have emerged as the AAV con-
struct of choice for viral vector targeting of astrocytes. Substitution
of the CMV minimal promoter with an astrocyte-speciﬁc pro-
moter derived from GFAP results in astrocyte-speciﬁc expression
of the transgene.
An example of an application of this technique in the study
of astrocyte biochemistry and function is recording Ca2+ ﬂuctua-
tions in astrocytes. Monitoring astrocyte Ca2+ activity continues
to be a primary technique in the study of astrocytes ever since
it was discovered in vitro that astrocyte Ca2+ elevations mod-
ulate neuronal excitability (Parpura et al., 1994; Araque et al.,
1998). Early approaches used commercially available membrane-
permeable AM ester forms of organic Ca2+ indicator dyes to
“bulk-load” and monitor changes in cytosolic Ca2+ concentra-
tion in astrocytes (Porter and McCarthy, 1996; Nett et al., 2002).
This technique offered the advantage of monitoring Ca2+ activity
in many astrocytes simultaneously, but at the cost of poor resolu-
tion of astrocyte processes that are the ﬁrst responders to neuronal
activity and which may operate autonomously from other astro-
cytic compartments. A derivative of this technique developed
more recently is “bolus-loading” in which the AM Ca2+ indi-
cator is pressure-ejected to load astrocytes with Ca2+ indicator
deeper in the tissue where cells and their connections are more
intact (Garaschuk et al., 2006). While this technique increases vis-
ibility of the larger astrocyte processes, it still suffers from low
signal-to-noise and difﬁculty differentiating between domains of
individual astrocytes due to high background labeling. Further-
more, a secondary label, such as sulforhodamine 101, is often
required to conﬁrm the loaded cells as astrocytes (Nimmerjahn
et al., 2004), but this indicator has been shown to alter neu-
ronal activity (Kang et al., 2010). Moreover, cell-impermeantCa2+
indicators delivered via patch pipette offer excellent signal-to-
noise and detection of Ca2+ events in small, bulk ﬁne processes
of astrocytes (Fiacco et al., 2007; Xie et al., 2012), but there is
some concern about dialysis of the cellular contents by the patch
pipette, especially in cases where the pipette is left in whole-
cell patch clamp mode during measurements which can dampen
Ca2+ signals. Last, while patch clamp delivery of Ca2+ indica-
tor to astrocytes is relatively straightforward in brain slices, this
approach is not as practical for recording astrocyte Ca2+ activity
in vivo.
Viral-mediateddelivery of GCaMPgenetically encoded calcium
indicators (GECIs) overcomes many of the limitations associated
with the traditional approaches described above. It can be thought
of as“high resolution bulk-loading” in that many astrocytes can be
monitored at once and with the excellent signal-to-noise offered
by the latest GCaMPs. Because the GECIs are delivered using
an astrocyte-speciﬁc promoter, no secondary labeling is neces-
sary to conﬁrm the cells as astrocytes. Studies have indicated very
speciﬁc transfection of astrocytes using this technique (Ortinski
et al., 2010; Xie et al., 2010; Shigetomi et al., 2013a). Recently,
Shigetomi et al. (2013a) used the AAV 2/5 vector to deliver a
Lck membrane tethered form of GCaMP3 to astrocytes. Not
only do the transfected astrocytes show signiﬁcantly more fre-
quent Ca2+ activity in ﬁne processes compared to bulk-loading
protocols (Shigetomi et al., 2013a), but because the indicator is
membrane-tethered, it can monitor Ca2+ activity in the smallest
“branchlets” and “leaﬂets” (Tong et al., 2013). Because Ca2+ activ-
ity monitored using the Lck-GCaMP3 indicator was diminished
by an inhibitor of TRPA1 channels, the data provide evidence
for astrocyte Ca2+ signals produced by a mechanism other than
IP3R2-mediated internal stores. It will be important to follow-up
this interesting ﬁnding in future studies by determining the rela-
tive ability of the Lck-GCaMP3 to detect TRPA1 vs. IP3R-mediated
Ca2+ elevations or mitochondrial Ca2+ dynamics (Parnis et al.,
2013) in astrocytes. For example, how much of the Ca2+ activity
detected by Lck-GCaMP3 is diminished by IP3R inhibitors? This
would help rule out possible non-speciﬁc effects of HC 030031,
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the drug used to block TRPA1 channels. Firmer evidence of the
TRPA1-mediated Ca2+ elevations could be provided by trans-
fecting IP3R2 KO mice with the Lck-GCaMP3 Ca2+ indicator
and determining the extent to which any remaining Ca2+ ele-
vations are blocked by the TRPA1 inhibitor. In summary, the
membrane-tethered version of the new astrocytic GECIs may be
specialized to distinguish among different sources of astrocyte
Ca2+, due to a combination of its location, excellent signal-to-
noise, and sensitivity to changes in Ca2+ concentration near the
membrane.
Like any technique, viral delivery methods are not without lim-
itations. GECIs have yet to be fully characterized. While they offer
the advantage of increasing understanding of Ca2+ microdomains
and conditions under which Ca2+ elevations occur, high levels
of expression may result in signiﬁcant calcium buffering with
unintended consequences. Perhaps a more signiﬁcant concern
associated with the use of AAV vectors is the possibility of induc-
ing reactive gliosis. Astrocytic Ca2+ signaling is disrupted in
reactive astrocytes, with typically exaggerated and more widely
propagating Ca2+ elevations and with increased propensity for
gliotransmitter release (reviewed in Agulhon et al., 2012). There-
fore, great care has been taken to determine the amount of
reactive astrocytosis (if any) apparent after viral transfection by
immunostaining for the astrocytic markers GFAP and vimentin
to look for astrocytic hypertrophy (Xie et al., 2010; Shigetomi
et al., 2013a). The AAV 2/5 vector was actually used purpose-
fully to induce astrogliosis to determine the effect on astrocyte
glutamine synthetase (GS) and neuronal excitability (Ortinski
et al., 2010). Ortinski et al. (2010) found a signiﬁcant increase
in neuronal excitability caused by reduced GABA synthesis in
neurons following loss of GS in reactive astrocytes. These data
were conﬁrmed by recovery of GABA transmission with exoge-
nous application of glutamine. High titers of AAV 2/5 caused
the astrogliosis and effects on neurons while low titers did not.
Subsequent studies have actually used even higher titers than
Ortinski et al. (2010), but reported normal astrocytic morphol-
ogy suggesting that the astrocytes were not reactive (Xie et al.,
2010; Shigetomi et al., 2013a). It is unclear what is behind these
disparate ﬁndings but one possibility is that Ortinski et al. used
the 638 bp GFAP Gfa104 promoter to target astrocytes, while
Xie et al. (2010) and Shigetomi et al. (2013a,b) used the 681 bp
GFAP gfaABC1D promoter. This is an important issue to con-
tinue to explore as there may be reactive changes induced by AAV
in astrocytes that are underway prior to overt gliosis and hyper-
trophy. Because astrogliosis in itself signiﬁcantly alters neuronal
excitability, care needs to be taken interpreting the role of astro-
cyte Ca2+ on neuronal activity using virally transfected GECIs.
Overall, the new astrocytic GECIs offer a tantalizing approach
to record astrocyte Ca2+ activity in vivo. Future studies will
help deﬁne limitations of viral-mediated GECI expression, lead-
ing to reﬁnement in both methodology and interpretation of
data.
IN UTERO GENE ELECTROPORATION STRATEGIES
One emerging methodology to manipulate gene expression in
astrocytes in vivo is by IUE. IUE is a method of gene deliv-
ery into mouse embryos (Fukuchi-Shimogori and Grove, 2001;
Saito and Nakatsuji, 2001; Takahashi et al., 2002), which has
become a method of choice for gain and loss of function
studies in embryonic CNS cell progenitors. The IUE method
involves injecting a plasmid DNA vector into the ventricles of
the embryonic brain, and then using electrical pulses to facil-
itate the transfer of the DNA into the progenitor cells of the
VZ/subventricular zone (SVZ). The optimal development stage
for using this method in mice is between embryonic day (E)
10.5 and E16.5. In order to obtain stable expression of a trans-
gene of interest in highly proliferative neural precursors and
their progeny, a combination of transposon-mediated gene trans-
fer into the host genome (Cary et al., 1989) with IUE has been
used. This approach enables the expression of a transgene stably
and efﬁciently in mitotic neural precursors (radial glia) during
development, and in both cortical astrocytes and oligodendro-
cytes, after birth (Ding et al., 2005; Cadinanos and Bradley,
2007; Wilson et al., 2007; VandenDriessche et al., 2009; Woltjen
et al., 2009; Yoshida et al., 2010; Chen and LoTurco, 2012). The
transposon system involves a transgene of interest from a donor
plasmid and a helper plasmid that expresses a transposase under
the control of a cell-speciﬁc promoter (Cadinanos and Bradley,
2007; Chen and LoTurco, 2012). For instance, by combining a
plasmid containing a transposase under the control of the GLAST
promoter with a donor plasmid containing the green ﬂuorescent
marker eGFP, astrocytes originating from GLAST positive pro-
genitors were labeled with eGFP in the cortex of P27 mice (Chen
and LoTurco, 2012). Using an alternate transposon system and
the GFAP and S100β promoters, stable postnatal expression of
eGFP was obtained in astrocytes of juvenile mice (generated from
GFAP- and S100β-expressing progenitors; Yoshida et al., 2010).
The relatively low number of astrocytes expressing eGFP allowed
the authors to trace the long-term lineage of glial progenitors
in vivo.
Tracing the long-term lineage of glial progenitor is of great
importance in the ﬁeld because of the growing evidence for astro-
cytic morphological, molecular, and functional heterogeneity.
Whether this heterogeneity is speciﬁed during brain develop-
ment is not clear. A recent study has addressed this question
and analyzed cell lineages thoroughly using IUE (Garcia-Marques
and Lopez-Mascaraque, 2013). Twelve plasmids containing the
sequences of six ﬂuorescent proteins, whose expression was driven
by the GFAP promoter in either the cytosol or the nucleus, were
used. After co-electroporation of the plasmid mixture with a plas-
mid encoding a transposase under the control of the ubiquitous
CMV promoter into ventricles of E14 embryos, the sequences
coding the ﬂuorescent markers were randomly inserted into
the genome of progenitor cells to generate many colors by a
combination of the ﬂuorescent proteins. This stochastic and
combinatorial expression of six ﬂuorescent proteins produces
inheritable markers for in vivo long-term tracing of glial pro-
genitor lineages (Garcia-Marques and Lopez-Mascaraque, 2013).
Unanticipated and highly speciﬁc clonal distribution in spe-
ciﬁc domains was revealed in the cortex of adult mice. More-
over, the authors found that different classes of astrocytes
emerge from different clones, reinforcing the view that lin-
eage origin deﬁnes astrocyte heterogeneity. The positional iden-
tity of these clones represents an additional level of astrocytic
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heterogeneity, which is likely associated with speciﬁc regional
functions. Interestingly, astrocytes of the same clone often
(but not always) responded equally to cortical injury, sug-
gesting the dependence of their genetic information. While
some clones exhibited strong morphological alteration follow-
ing injury, other clones located similar distances from the lesion
were unresponsive, suggesting that the developmentally deter-
mined features of different astrocytic clones should not be
overlooked when developing brain therapies (Martin-Lopez et al.,
2013).
In addition to the use of astrocyte-speciﬁc promoters to drive
transgene expression in postnatal astrocytes, conditional CreERT2
systems have also been combined with IUE to induce cell- and
time-speciﬁc expression of transgenes (Matsuda and Cepko, 2007;
LoTurco et al., 2009), widening the set of possible genetic manipu-
lations using IUE. Therefore, although the IUE technology has
been used mainly for descriptive analysis so far, it is likely to
become an important tool more commonly used in the ﬁeld.
The relative ease of implementation and inherent ﬂexibility of a
plasmid-based system should make this method valuable to many
investigators interested inmarking andmanipulating glial progen-
itor lineages in the CNS of species for which Cre reporter lines are
not available (e.g., rats). Additionally, one of the advantages of the
IUE approach over the generation of transgenic mice is that it is
both cheaper and less time consuming. Furthermore, compared
to surgical viral transfer performed postnatally, it is less invasive.
The introduction of transgenes in astrocytes through IUE, when
the immune system is immature, does not produce overt reactive
gliosis thereby enabling study of astrocytes in a more physiological
context compared to viral-based approaches. However, limitations
of IUE include variable electroporation efﬁciency, promoter leak-
iness, and difﬁculty in precisely controlling the number of labeled
astrocytes.
STUDYING ASTROCYTE FUNCTION THROUGH GENETIC
MANIPULATION OF HUMAN GLIAL PROGENITORS
Although the molecular approaches described above have led to
important steps forward in deciphering some of the functions
of astrocytes in the pathophysiology of the mammalian brain,
an important question remains: can the ﬁndings obtained from
studies of the rodent brain be extrapolated to human astro-
cytes? There is mounting evidence that rodent astrocytes have
multiple key functions in the developing and adult nervous sys-
tem, including roles in synapse formation and function, working
memory, autonomic and locomotor functions, and cognition
(Barres, 2008; Halassa and Haydon, 2010; Lioy et al., 2011; Han
et al., 2012; Molofsky et al., 2012; Wang et al., 2012a; Agulhon
et al., 2013; Clarke and Barres, 2013). However, human astro-
cytes are both morphologically and functionally distinct from
those of rodents (Colombo, 1996; Oberheim et al., 2009). There-
fore, do human astrocytes have unique properties compared to
their rodent counterparts, which could explain the higher cogni-
tive abilities of humans? This fascinating question in the ﬁeld has
been recently explored by the groups of Maiken Nedergaard and
Steven Goldman (Han et al., 2013).
In this study, the authors used human glial chimeric mouse
brains to ask whether human astrocytes have unique properties
that can inﬂuence activity-dependent synaptic plasticity ex vivo
and learning and memory in vivo. To do so, they used human glial
progenitor cells (GPCs) obtained by magnetic-assisted cell sorting
using antibodies against PSA-NCAM and A5B5 cell surface anti-
gens. The A2B5+/PSA-NCAM− glial cells were expanded via a cell
cultured protocol that promoted differentiation into astrocytes.
Prior to transplantation into brains of neonatal immune-deﬁcient
mice,GPCswere transducedusing aVSVg-pseudotyped lentiviral-
CMC-EGFP in order to label them with a GFP. Once transplanted,
mice matured to become adult chimeras for both mouse and
human astrocytes (Windrem et al., 2004, 2008), and their brains
were analyzed in adult mice. Human-derived cells survived in
the rodent host brains and inﬁltrated the cortex and hippocam-
pus to give rise to some EGFP+ astrocytes. Human astrocytes
retained the large size and complex morphology that was previ-
ously reported in humanbrains (Oberheim et al., 2009), indicating
that they matured in a cell-autonomous fashion. Additionally,
human astrocytes extended processes contacting blood vessels
and displayed long and tortuous processes, a phenotype typically
observed in a specialized subpopulation of interlaminar astrocytes
in the cortical white matter of adult human brains (Oberheim
et al., 2009). Another type of engrafted human astroglial cell exhib-
ited varicosity-studdedprocesses (Kettenmann andRansom,2005;
Oberheim et al., 2009). Finally, human astrocytes occupied dis-
tinct non-overlapping domains and formed gap junctions with
rodent host astrocytes. At the physiological level, the input resis-
tance of human astrocytes was twice as large as those of mouse
astrocytes and Ca2+ signals propagated threefold faster than in
mouse astrocytes. Notably, using acute hippocampal slices, Han
et al. (2013) observed that the slope of fEPSPs was steeper and
LTP was stronger and longer-lasting in mice grafted with human
astrocytes compared to mice grafted with mouse astrocytes, indi-
cating that excitatory synaptic transmission was enhanced in the
presence of human astrocytes. Thus, enhancement of LTP was
a speciﬁc characteristic of human glial cells. Interestingly, the
potentiation of fEPSPs in human glial chimeric mice and the
enhancement of LTP did not result from higher expression of
NMDA receptors, increased synaptic release of glutamate, altered
adenosine tone or increased glial release of D-serine. Rather it
was found that human astrocytes facilitated synaptic insertion
of the GluR1 subunit in host murine neurons through a TNFα-
dependent, PKC/CaMKII-mediated pathway, consistent with the
potentiation of AMPA receptor-mediated currents, thus lower-
ing the threshold for induction of LTP in human glial chimeric
mice. Strikingly, human glial chimeric mice performed better in
hippocampus-mediated learning tasks compared to their untrans-
planted littermates. Together, these ﬁndings suggest that human
astrocytes may have some unique properties to enhance cognition.
This study represents an important scientiﬁc and technological
step forward to study the function of human astrocytes in live
adult brains, which has not been possible so far. It also illustrates
the power of combining different technological advancements
together in live animals. It was unclear in the study if vari-
cose projection astrocytes were present only in cortical layers 5
and 6 as discovered previously in human temporal neocortex,
or if these cells were present throughout the cortex and hip-
pocampus in the chimeric mice. Abnormal expression of varicose
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projection astrocytes in the hippocampus may in part explain
some of the unique cognitive abilities in these animals. In addi-
tion, further investigation will be needed to determine whether the
enhanced cognitive performance of the humanized mice is specif-
ically due to human astrocytes, or whether the progenitor cells
that did not differentiate into mature astrocytes contributed to the
phenotype.
SUMMARY AND FUTURE DIRECTIONS
Important advances continue to be made in development of
molecular tools to understand astrocyte function and the effect
of manipulating individual astrocytic signaling molecules on neu-
ronal activity and pathophysiology of the brain in vivo. Several
examples have been provided in this review, including generation
of conditional and inducible genetically engineered mouse lines
for selective expression or removal of speciﬁc astrocyte proteins,
as well as viral- or IUE-mediated gene delivery techniques for
the study of astrocyte function. Study of astrocyte Ca2+ activity
continues to be heavily emphasized, and while there is certainly
more to discover in this area, there is an incredibly diverse array
of other astrocytic GPCRs, ion channels, transporters, and sig-
naling molecules to explore. Recent development of new lines
using chemogenetics is one such example to further understand
the importance of astrocytic signaling pathways in health and dis-
ease in vivo. The effect of selectively perturbing or stimulating
other signaling molecules in astrocytes, such as G proteins, protein
kinases, cAMP,diacylglycerol, phospholipase C, and phosphoinos-
itol isoforms may open up new areas of research on astrocytes.
Furthermore, a greater appreciation of astrocyte heterogene-
ity in different brain areas or even between adjacent synapses
calls for the need to develop selective markers to identify astro-
cyte subtypes and molecular approaches to manipulate speciﬁc
astrocyte subpopulations. Another recent molecular approach
only just underway is understanding the effects of enhanced
DNA methylation or de-methylation (epigenetic mechanisms) on
astrocyte protein expression and function in development and
disease. Finally, there has been a strong tendency to focus on the
immediate, short-term consequences of manipulating astrocyte
receptors and signaling molecules on neuronal activity and brain
function. Based on the predominance of metabotropic signaling
cascades in astrocytes and the role of astrocytes in homeostasis of
the synaptic microenvironment, the role of astrocyte-to-neuron
communication may be tuned toward long-term regulatory func-
tions. Therefore, another area of future study is to examine the
outcome of stimulating astrocytic signaling cascades on gene
transcription, synthesis of new proteins, and long-term regula-
tion of cellular processes in neurons, astrocytes, and other glial
cell types.
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